YU17891A - Dnk koja odgovara genomu virusa sa negativnim lancem rnk, i postupak za dobijanje infektivnih virusa sa negativnim lancem rnk - Google Patents
Dnk koja odgovara genomu virusa sa negativnim lancem rnk, i postupak za dobijanje infektivnih virusa sa negativnim lancem rnkInfo
- Publication number
- YU17891A YU17891A YU17891A YU17891A YU17891A YU 17891 A YU17891 A YU 17891A YU 17891 A YU17891 A YU 17891A YU 17891 A YU17891 A YU 17891A YU 17891 A YU17891 A YU 17891A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- negative
- rna
- strand
- viruses
- chain
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 230000002458 infectious effect Effects 0.000 title abstract 3
- 241000712079 Measles morbillivirus Species 0.000 abstract 4
- 239000002299 complementary DNA Substances 0.000 abstract 3
- 241001493065 dsRNA viruses Species 0.000 abstract 2
- 238000005516 engineering process Methods 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
DNK KOJA ODGOVARA GENOMU VIRUSA SA NEGATIVNIM LANCEM RNK, I POSTUPAK ZA DOBIJANJE INFEKTIVNIH VIRUSA SA NEGATIVNIM LANCEM RNK, sadašnji pronalazak se, u načelu, odnosi na metodologiju pogodnu za dobijanje infektivnih virusa sa negativnim lancem, korisnih za upotrebu u vakcinama, iz klonirane komplementarne dezoksiribonukleinske kiseline (cDNK). Pronalazak se konkretno odnosi na molekule cDNK i na pomoćne ćelije koje su korisne kao orudje u ovoj metodologiji, kao i na karakterizaciju dobijenih virusa. Kao model za RNK-viruse sa negativnim lancem korišćen je virus malih boginja (MV). Opisani pronalazak obezbedjuje tehnologiju za konstruisanje rekombinantnih vakcinskih sojeva MV koji kodiraju epitope ili kompletne proteine iz heterolognih virusa, bakterija ili parazita. Uz male modifikacije opisane tehnologije kao vektor, umesto MV, može da se koristi bilo koji RNK-virus sa negativnim lancem.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90102120 | 1990-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU17891A true YU17891A (sh) | 1994-09-09 |
Family
ID=8203580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU17891A YU17891A (sh) | 1990-02-02 | 1991-02-01 | Dnk koja odgovara genomu virusa sa negativnim lancem rnk, i postupak za dobijanje infektivnih virusa sa negativnim lancem rnk |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0440219A1 (sh) |
JP (1) | JPH04211377A (sh) |
AU (1) | AU7007491A (sh) |
CA (1) | CA2035386A1 (sh) |
YU (1) | YU17891A (sh) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569679B1 (en) | 1988-03-21 | 2003-05-27 | Chiron Corporation | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene |
US6241982B1 (en) | 1988-03-21 | 2001-06-05 | Chiron Corporation | Method for treating brain cancer with a conditionally lethal gene |
DE69033975T2 (de) * | 1989-01-23 | 2002-10-02 | Chiron Corp | Rekombinanttherapien für Infektionen und hyperproliferative Störungen |
JP3045581B2 (ja) * | 1991-10-14 | 2000-05-29 | 社団法人北里研究所 | 麻疹ワクチンウイルス株同定方法 |
ZA937164B (en) * | 1992-09-28 | 1994-05-23 | Commw Scient Ind Res Org | Delivery system |
JPH09503920A (ja) | 1993-11-18 | 1997-04-22 | チロン ビアジーン,インコーポレイティド | 条件致死遺伝子を利用する組成物及び方法 |
ATE257175T1 (de) * | 1994-07-18 | 2004-01-15 | Conzelmann Karl Klaus Prof Dr | Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus |
US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
US5750396A (en) * | 1995-05-08 | 1998-05-12 | St. Judes Children's Research Hospital | Stable virus packaging cell lines |
DE69510207T3 (de) | 1995-08-09 | 2007-02-15 | Schweiz. Serum- & Impfinstitut Bern | Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren |
US7485440B2 (en) | 1995-09-27 | 2009-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
US6689367B1 (en) | 1995-09-27 | 2004-02-10 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
US7846455B2 (en) | 1996-07-15 | 2010-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated chimeric respiratory syncytial virus |
EP0864645B9 (en) * | 1995-10-31 | 2006-03-22 | Dnavec Research Inc. | Negative-strand rna virus vector having autonomously replicating activity |
EP0863202B1 (en) * | 1995-11-01 | 2010-06-09 | Dnavec Research Inc. | Recombinant sendai virus |
AU7335396A (en) * | 1995-11-01 | 1997-05-22 | Dnavec Research Inc. | Membrane-fusible liposome with the use of recombinant sendai virus |
US6699476B1 (en) | 1996-07-15 | 2004-03-02 | Peter L. Collins | Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules |
EP2112220A3 (en) | 1996-07-15 | 2010-01-06 | The Government of the United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
WO1998012332A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
AU4427897A (en) * | 1996-09-27 | 1998-04-17 | American Cyanamid Company | 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales |
EP0839912A1 (en) * | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US7632508B2 (en) | 1997-05-23 | 2009-12-15 | The United States Of America | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
US20030082209A1 (en) | 2000-07-05 | 2003-05-01 | Skiadopoulos Mario H. | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
US7314631B1 (en) | 1997-05-23 | 2008-01-01 | The United States Of America As Represented By The Department Of Health And Human Services | Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV) |
US7250171B1 (en) | 1997-05-23 | 2007-07-31 | United States Of America As Represented By The Dept. Of Health & Human Services | Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein |
AU7797798A (en) * | 1997-05-23 | 1998-12-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
US7208161B1 (en) | 1997-05-23 | 2007-04-24 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
US7951383B2 (en) | 1997-05-23 | 2011-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated parainfluenza virus (PIV) vaccines |
US7201907B1 (en) | 1997-05-23 | 2007-04-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines |
US6410023B1 (en) | 1997-05-23 | 2002-06-25 | United States Of America | Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
WO1999006576A1 (en) | 1997-08-04 | 1999-02-11 | Calydon, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
US6830748B1 (en) | 1997-09-26 | 2004-12-14 | Medimmune Vaccines, Inc. | Recombinant RSV virus expression systems and vaccines |
CA2308606A1 (en) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
BR9910089A (pt) | 1998-05-01 | 2004-06-08 | Chiron Corp | Composições e antìgenos de neisseria meningitidis |
EP1121437B1 (en) | 1998-10-15 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Metastatic breast and colon cancer regulated genes |
ES2310055T3 (es) | 1998-12-16 | 2008-12-16 | Novartis Vaccines & Diagnostic | Quinasa humana dependiente de ciclina (hpnqalre). |
JP3961222B2 (ja) | 1999-03-08 | 2007-08-22 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | Prrsvワクチン |
US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
CA2370372C (en) | 1999-04-22 | 2009-02-24 | United States Department Of Agriculture | Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142 |
RU2245366C2 (ru) | 1999-04-30 | 2005-01-27 | Чирон С.Р.Л. | Антиген neisseria, кодирующая его нуклеиновая кислота, их использование |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
EP1287152B1 (en) | 1999-07-09 | 2008-12-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Human-bovine chimeric respiratory syncytial virus vaccines |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
MXPA02001177A (es) * | 1999-08-02 | 2002-07-02 | Wyeth Corp | Recuperacion del virus de las paperas del acido desoxirribonucleico recombinante. |
EP2275552B1 (en) | 1999-10-29 | 2015-09-09 | GlaxoSmithKline Biologicals SA | Neisserial antigenic peptides |
PT2289545T (pt) | 2000-01-17 | 2016-09-06 | Glaxosmithkline Biologicals Sa | Vacina de omv suplementada contra meningococos |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
US20020165192A1 (en) | 2000-09-19 | 2002-11-07 | Kerr William G. | Control of NK cell function and survival by modulation of ship activity |
US7691821B2 (en) | 2001-09-19 | 2010-04-06 | University Of South Florida | Inhibition of SHIP to enhance stem cell harvest and transplantation |
MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
WO2002098457A2 (en) * | 2001-01-17 | 2002-12-12 | Thomas Jefferson University | Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
ES2312649T3 (es) | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Inmunizacion frente a chlamydia trachomatis. |
ES2427139T3 (es) | 2002-06-20 | 2013-10-29 | Institut Pasteur | Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna |
ATE437175T1 (de) | 2002-06-20 | 2009-08-15 | Pasteur Institut | Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen |
EP2279746B1 (en) | 2002-11-15 | 2013-10-02 | Novartis Vaccines and Diagnostics S.r.l. | Surface proteins in neisseria meningitidis |
CA2432738A1 (en) * | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US7763592B1 (en) | 2003-11-20 | 2010-07-27 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
US7807646B1 (en) | 2003-11-20 | 2010-10-05 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
PT1736541E (pt) | 2004-03-29 | 2013-01-31 | Galpharma Co Ltd | Nova proteína galectina 9 modificada e sua utilização |
AR049924A1 (es) | 2004-06-18 | 2006-09-13 | Univ Minnesota | Identificacion de organismos viralmente infectados y vacunados |
US7632636B2 (en) | 2004-09-21 | 2009-12-15 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome isolates and methods of use |
ES2386973T3 (es) | 2005-06-24 | 2012-09-10 | Regents Of The University Of Minnesota | Virus PRRS, clones infecciosos, mutantes de los mismos, y métodos de utilización |
US20110206692A1 (en) | 2006-06-09 | 2011-08-25 | Novartis Ag | Conformers of bacterial adhesins |
EP2139447A2 (en) | 2007-03-20 | 2010-01-06 | Harold Brem | Gm-csf cosmeceutical compositions and methods of use thereof |
AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
ME02271B (me) | 2011-02-17 | 2016-02-20 | Boehringer Ingelheim Vetmedica Gmbh | Novi evropski prrsv soj |
DK2675476T3 (en) | 2011-02-17 | 2015-12-14 | Boehringer Ingelheim Vetmed | Process for producing PRRSV on a commercial scale |
US9187731B2 (en) | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
WO2013017568A1 (en) | 2011-07-29 | 2013-02-07 | Boehringer Ingelheim Vetmedica Gmbh | INFECTIOUS cDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF |
EP2968513A2 (en) | 2013-03-15 | 2016-01-20 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use |
CA2953917C (en) | 2013-07-01 | 2021-10-19 | The Research Foundation For The State University Of New York | Ship inhibition to combat obesity |
EP3157529B1 (en) | 2014-06-17 | 2021-08-04 | The Research Foundation for The State University of New York | Ship inhibition to induce activation of natural killer cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0237686A1 (en) * | 1986-03-18 | 1987-09-23 | Institut Pasteur | DNA sequences derived from the rabies virus genome |
-
1991
- 1991-01-30 AU AU70074/91A patent/AU7007491A/en not_active Abandoned
- 1991-01-31 EP EP91101278A patent/EP0440219A1/en not_active Withdrawn
- 1991-01-31 CA CA002035386A patent/CA2035386A1/en not_active Abandoned
- 1991-02-01 YU YU17891A patent/YU17891A/sh unknown
- 1991-02-02 JP JP3033522A patent/JPH04211377A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2035386A1 (en) | 1991-08-03 |
AU7007491A (en) | 1991-08-08 |
EP0440219A1 (en) | 1991-08-07 |
JPH04211377A (ja) | 1992-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU17891A (sh) | Dnk koja odgovara genomu virusa sa negativnim lancem rnk, i postupak za dobijanje infektivnih virusa sa negativnim lancem rnk | |
ES2335395T3 (es) | Metodo mejorado para la produccion a escala de antigenos virales. | |
Takeda et al. | Recovery of pathogenic measles virus from cloned cDNA | |
Bukreyev et al. | Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates | |
ES2265991T5 (es) | Medio para el cultivo de células libre de proteínas y de suero | |
JP6084359B2 (ja) | 細胞を培養するための動物性タンパク質非含有培地 | |
US5789229A (en) | Stranded RNA virus particles | |
Escriou et al. | Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein | |
Murphy et al. | Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics | |
Del Valle et al. | A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge | |
KR20030032923A (ko) | 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 | |
ATE469972T1 (de) | Multiplasmid-system zur erzeugung des grippevirus | |
DE60033284D1 (de) | In vitro-rekonstitution von segmentierten, negativstrang-rna-viren | |
IL145702A (en) | Method of preparing infectious influenza viruses in the absence of a helper virus | |
DE69740002D1 (de) | Tierzellen und verfahren für die replikation von influenza viren | |
ATE482714T1 (de) | Modifizierter hitzeschockprotein-antigenpeptid- komplex | |
WO2000061737A3 (en) | Production of attenuated negative stranded RNA virus vaccines | |
Morimoto et al. | Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity | |
Li et al. | A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice | |
Garcı́a-Sastre et al. | Influenza virus vectors | |
ATE354370T1 (de) | Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen | |
DK1334197T3 (da) | Gær-afledt vaccine mod IPNV | |
ATE427119T1 (de) | Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung | |
CN105886531A (zh) | 分子标记猪瘟病毒弱毒疫苗的构建方法 | |
KR20110092280A (ko) | pH에 안정한 외피보유 바이러스의 생산 방법 |